Disintegrant PVPP, commonly called crospovidone, is an insoluble, crosslinked form of polyvinylpyrrolidone used as a tablet disintegrant. It helps a tablet break apart after contact with liquid, supporting the release of its ingredients for subsequent dissolution. For formulators, the right grade and use level depend on the formulation, manufacturing process, and required product performance. A practical starting point is to compare supplier specifications and evaluate crospovidone in the actual tablet design rather than selecting it by name alone.
This guide is intended for pharmaceutical product developers, formulation scientists, procurement teams, and excipient distributors evaluating crospovidone for tablet applications. It is also relevant to buyers comparing PVPP grades or qualifying an additional supplier. The information is a general selection framework, not a substitute for formulation development, regulatory review, or product-specific testing. Final decisions should be based on the intended market and the applicable quality requirements.
Crospovidone is crosslinked polyvinylpyrrolidone (PVP), also described as insoluble PVP or PVPP. Unlike soluble PVP grades commonly used as binders, its crosslinked structure does not dissolve in water under ordinary use conditions. In a tablet, crospovidone is used as a superdisintegrant: it promotes tablet breakup when liquid enters the compact. Its effectiveness depends on the full formulation and manufacturing conditions, so the ingredient name alone cannot predict finished-tablet performance.
Disintegration is not the same as dissolution. A disintegrant helps a tablet break into smaller particles, while dissolution describes the process by which an ingredient goes into solution. Disintegration may influence the conditions for dissolution, but it does not guarantee a particular dissolution profile or clinical outcome. Both properties should be assessed using appropriate product-specific methods.
Crospovidone is principally selected for solid oral dosage forms, including tablets, when rapid tablet breakup is a formulation objective. It may be considered in direct compression or wet granulation, depending on the grade and process design. Formulators can evaluate it as an intragranular ingredient, an extragranular ingredient, or in both locations. The choice should be confirmed experimentally because granulation, compression, and the other excipients can affect results.
Suppliers may offer different crospovidone grades that vary in characteristics such as particle-size distribution and bulk handling properties. Grade designations are supplier-specific and should not be assumed to be interchangeable. Review the supplier’s current technical data sheet and certificate of analysis for the exact material offered. Where a specification or compendial requirement applies, confirm that the offered grade and its documentation meet the intended product and market needs.
| Selection point | What to review | Why it matters |
|---|---|---|
| Identity and grade | Product name, grade designation, and material description | Confirms that the proposed material is the intended crosslinked PVP grade. |
| Particle characteristics | Supplier-reported particle-size data and test method | May affect powder handling, blending, and formulation behavior. |
| Quality documentation | Specification, certificate of analysis, and available quality documents | Supports incoming-material review and supplier qualification. |
| Supply conditions | Packaging, order quantity, lead time, and shipment terms | Helps assess sourcing fit for trials and routine production. |
Start by documenting the tablet type, target performance, manufacturing route, and markets where the product may be sold. Identify the applicable product-specific disintegration and dissolution requirements rather than assuming one time limit fits every tablet. Record relevant formulation constraints, such as moisture sensitivity, compression behavior, and the properties of the active ingredient. This gives the supplier and formulation team a clear basis for grade evaluation.
You will get efficient and thoughtful service from NKY Group.
A commonly cited starting range for crospovidone in tablet formulations is approximately 2–5% by weight. Treat this as a screening range, not a universal recommendation or a guaranteed optimum; the actual amount depends on the formulation and process. A development team might compare trial formulations at 2%, 3%, and 5% by weight as an initial, explicitly experimental screening plan. Evaluate each trial against the product’s own acceptance criteria and confirm that other formulation properties remain suitable.
Next, compare addition strategies. Intragranular addition places the material in the granulation blend, while extragranular addition places it outside the granules before final compression. Some formulations may be assessed using both approaches, but there is no single placement strategy that is best for every product. Document the selected addition point and process conditions so that results can be interpreted and reproduced.
Test the complete formulation, not only the raw excipient, using suitable methods for the intended dosage form. Depending on the development plan, evaluation may include disintegration, dissolution, tablet hardness or tensile strength, friability, and manufacturing behavior. Use a defined protocol and consider whether results remain acceptable across relevant process settings. A change in disintegration should be interpreted alongside the tablet’s other quality attributes.
Before placing a commercial order, request the current product specification, a representative certificate of analysis, and any other quality documents required by your qualification process. Confirm packaging, storage guidance, available order quantities, sample availability, lead time, and shipment terms directly with the supplier. These details can vary by product, destination, and order, so they should be confirmed in the quotation rather than assumed. For a new supplier, establish how changes to the material or documentation will be communicated.
Crospovidone pricing and supply conditions depend on the specific grade, order quantity, packaging, destination, and current availability. There is no single reliable price, minimum order quantity, or lead time that applies to every supplier and transaction. Buyers should request a quotation for both development and expected production needs, and clarify whether sample quantities are available. When comparing offers, assess documentation and supply conditions alongside unit price.
Choose a supplier that can clearly identify the material and provide the documentation your quality system requires. Ask how the supplier supports sample evaluation, technical questions, and order planning, and confirm which services are available for the specific grade. Check that commercial terms and delivery expectations are stated clearly in the quotation. NKY Group can discuss crospovidone sourcing requirements with B2B buyers and help clarify product, documentation, and quotation needs based on the intended application.
Crospovidone is an insoluble, crosslinked PVP used to help tablets disintegrate, but selection should be based on the formulation, manufacturing process, quality requirements, and supply fit. Begin by defining product targets, then compare suitable grades and screen a justified use level in the finished tablet. Verify performance with product-specific testing and review supplier documentation before qualification. To discuss a potential grade, sample, or quotation, contact NKY Group with your application, target market, estimated requirement, and documentation needs.
For more Disintegrant pvppinformation, please contact us. We will provide professional answers.